ログイン

2

2
23問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    Given a situation where screening cells, major crossmatch, autocontrol, and DAT (anti-IgG) are all positive, what procedure should be performed next? A. Adsorption using rabbit stroma B. Antigen typing of patient cells C. Elution followed by a cell panel on the eluate D. Selected cell panel

    C. Elution followed by a cell panel on the eluate

  • 2

    A major crossmatch and screening cells are 2+ at IS, 1+ at 37°C, and negative at the IAT phase. Identify the most likely problem. A. Combination of antibodies B. Cold alloantibody C. Rouleaux D. Test error

    B. Cold alloantibody

  • 3

    What corrective action should be taken when rouleaux causes positive test results? A. Perform a saline replacement technique B. Perform an autoabsorption C. Run a panel D. Perform an elution

    A. Perform a saline replacement technique

  • 4

    All of the following are reasons for performing an adsorption, except: A. Separation of mixtures of antibodies B. Removal of interfering substances C. Confirmation of weak antigens on red cells D. Identification of antibodies causing a positive DAT

    D. Identification of antibodies causing a positive DAT

  • 5

    How long must a recipient sample be kept in the blood bank following compatibility testing? A. 3 days B. 5 days C. 7 days D. 10 days

    C. 7 days

  • 6

    What is the crossmatching protocol for platelets and/or plasma? A. Perform a reverse grouping on donor plasma B. No testing is required C. Perform a reverse grouping on recipient plasma D. Platelets must be HLA compatible

    B. No testing is required

  • 7

    What are the compatibility requirements for an autologous unit? A. ABO and Rh typing B. Type and screen C. Major crossmatch D. All of these options

    A. ABO and Rh typing

  • 8

    A patient types as AB positive. Two units of blood have been ordered by the physician. Currently, the inventory shows no AB units, 10 A-positive units, 1 A-negative unit, 5 B-positive units, and 20 O-positive units. Which should be set up for the major crossmatch? A. A-positive units B. O-positive units C. B-positive units D. Call another blood supplier for type-specific blood

    A. A-positive units

  • 9

    Which of the following comprises an abbreviated crossmatch? A. ABO, Rh, and antibody screen B. ABO, Rh, antibody screen, IS crossmatch C. Type and screen D. ABO, Rh, IS crossmatc

    B. ABO, Rh, antibody screen, IS crossmatch

  • 10

    When may an IS crossmatch be performed? A. When a patient is being massively transfused B. When there is no history of antibodies and the current antibody screen is negative C. When blood is being emergency released D. When a patient has not been transfused in the past 3 months

    B. When there is no history of antibodies and the current antibody screen is negative

  • 11

    A patient had a transfusion reaction to packed red blood cells. The medical laboratory scientist began the laboratory investigation of the transfusion reaction by assembling pre- and post-transfusion specimens and all paperwork and computer printouts. What should he do next? A. Perform a DAT on the post-transfusion sample B. Check for a clerical error(s) C. Repeat ABO and Rh typing of patient and donor unit D. Perform an antibody screen on the posttransfusion sample

    B. Check for a clerical error(s)

  • 12

    What is the pathophysiological cause surrounding anaphylactic and anaphylactoid reactions? A. Antibody in patient serum is detected 3–7 days after transfusion, and is attached to donor red blood cells B. Donor plasma has reagins (IgE or IgA) that combine with allergens in patient plasma C. Patient is deficient in IgE and develops IgE antibodies via sensitization from transfusion or pregnancy D. Patient is deficient in IgA and develops IgA antibodies via sensitization from transfusion or pregnancy

    D. Patient is deficient in IgA and develops IgA antibodies via sensitization from transfusion or pregnancy

  • 13

    A patient has a hemolytic reaction to blood transfused 8 days ago. What is the most likely cause? A. Immediate, nonimmunologic probably due to volume overload B. Delayed immunologic, probably due to an antibody such as anti-Jka C. Delayed nonimmunologic, probably due to iron overload D. Immediate, immunologic, probably due to clerical error, ABO incompatibility

    B. Delayed immunologic, probably due to an antibody such as anti-Jka

  • 14

    What may be found in the serum of a person who is exhibiting signs of TRALI (transfusion-related acute lung injury)? A. Red blood cell alloantibody B. IgA antibody C. Antileukocyte antibody D. Allergen

    C. Antileukocyte antibody

  • 15

    Which type of transfusion reaction occurs in about 1% of all transfusions, results in a temperature rise of 1°C or higher, is associated with blood component transfusion, and is not related to the patient’s medical condition? A. Immediate hemolytic B. Delayed hemolytic C. Febrile nonhemolytic reaction D. Transfusion-related acute lung injury

    C. Febrile nonhemolytic reaction

  • 16

    What would be the result of group A blood given to an O patient? A. Nonimmune transfusion reaction B. Immediate hemolytic transfusion reaction C. Delayed hemolytic transfusion reaction D. Febrile nonhemolytic transfusion reaction

    B. Immediate hemolytic transfusion reaction

  • 17

    Patient DB received 2 units of group A-positive red cells 2 days ago. Two days later, he developed a fever and appeared jaundiced. His blood type was A positive. A transfusion reaction workup was ordered. There were no clerical errors detected. A post-transfusion specimen was collected and a DAT performed. The DAT was positive with monospecific anti-IgG. The plasma was also hemolyzed. An antibody screen and panel studies revealed the presence of anti-Jkb (postspecimen). The antibody screen on the pretransfusion specimen was negative. Which of the following explain the positive DAT? A. The donor cells had a positive DAT B. The donor cells were polyagglutinable C. The donor cells were likely positive for the Jkb antigen D. The recipient cells were likely positive for the Jkb antigen

    C. The donor cells were likely positive for the Jkb antigen

  • 18

    All of the following are part of the preliminary evaluation of a transfusion reaction, except: A. Check pre- and post-transfusion samples for color of serum B. Perform ABO and Rh recheck C. DAT on the post-transfusion sample D. Panel on pre- and post-transfusion samples

    D. Panel on pre- and post-transfusion samples

  • 19

    A 68-year-old female diagnosed with neutropenia and inflammation of the left hand was typed as A positive, and received 1 packed red blood cell unit. The antibody screen was negative and crossmatch was compatible. During the transfusion, her pulse was 94, and blood pressure rose from 114/59 to 132/64. Her temperature rose from 37.1°C pretransfusion to 37.8°C 60 minutes after starting transfusion, then to 38.1°C upon completion. A post-transfusion specimen yielded plasma that was neither hemolyzed nor icteric, and a negative DAT. Post-transfusion urinalysis gave a 1+ blood and protein with 10 RBCs/hpf microscopically. The clerical check was acceptable. What type of reaction most likely occurred as a result of transfusion? A. Allergic B. Circulatory overload C. Febrile nonhemolytic D. Delayed hemolytic

    C. Febrile nonhemolytic

  • 20

    A 92-year-old male diagnosed with anemia and episodes of frequent falling was typed as B negative and transfused 1 unit of packed red blood cells, also B negative. He was not recently transfused, and the antibody screen was negative. During the transfusion, his temperature rose from 36.2°C to 36.4°C, his pulse rose from 96 to 124, respirations from 18 to 20, and BP from 127/81 to 174/83. He was transfused with 205 mL before a reaction was called by the transfusionist. The postspecimen DAT was negative and clerical check acceptable. Urinalysis yielded 1+ blood with 5 RBCs microscopically. Other symptoms included tachycardia and flushing. What reaction had most likely taken place? A. Febrile nonhemolytic B. Acute hemolytic C. Anaphylactic D. Volume overload

    D. Volume overload

  • 21

    A 76-year-old female diagnosed with urosepsis was transfused 2 units of packed red blood cells. Her type was AB positive with a negative antibody screen. The units transfused were AB positive. Upon receiving the second unit, the patient became hypoxic with tachypnea. The clerical check was acceptable and DAT negative. She received 269 mL from the second unit before a reaction was called. Her temperature fell from 38°C to 36.4°C, her pulse increased from 72 to 90, and respirations rose from 35 to 41. Her BP was 110/70. The patient expired approximately 12 hours from the time the reaction was called. What type of reaction was most likely present? A. Febrile B. Symptoms not related to transfusion C. Allergic D. TRALI

    B. Symptoms not related to transfusion

  • 22

    A 52-year-old male received 2 units of packed red blood cells as an outpatient in the IV therapy unit. He had a 20-year history of head trauma and was quadriplegic. He had recurrent pneumonia and hematuria due to removal of a Foley catheter. His blood type was A positive with a previously identified anti-Fya. There was an ABO discrepancy in that the A1 cells were positive. The technologist attributed the reaction to the Fya antigen being present on the A1 cells. The patient also had a cold autoantibody. Two units of A-positive packed cells were crossmatched that were Fya negative, and were compatible. One unit was transfused at 11:30 a.m. without incident. The second unit was transfused at 2:16 p.m., and stopped at 3:55 p.m. due to reddish brown–tinged urine discovered in his collection bag. A post-transfusion specimen yielded a positive DAT, and plasma that was grossly hemolyzed. A prewarm crossmatch was incompatible in both the pre- and postspecimen. Anti-E and c were present in the postspecimen. What reaction was most likely present? A. Acute hemolytic B. Febrile C. Allergic D. TRALI

    A. Acute hemolytic

  • 23

    An 82-year-old male was admitted for renal failure. His type was B positive, and his antibody screen was negative. Two units of red cells were ordered. The first unit was transfused at 1:00 p.m. without incident. The second was started at 4:15 p.m. and stopped at 5:12 p.m., after the nurse observed the patient had expired. Vital signs were taken at 4:30 p.m. with no abnormalities. A transfusion reaction was called and the blood unit, tubing, and paperwork sent to the blood bank. There were no clinical manifestations noted on the paperwork and no post-transfusion specimen was sent to the blood bank. What type of reaction most likely occurred? A. Symptoms not related to transfusion B. Acute hemolytic reaction C. Anaphylactic reaction D. Volume overload

    A. Symptoms not related to transfusion

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    Given a situation where screening cells, major crossmatch, autocontrol, and DAT (anti-IgG) are all positive, what procedure should be performed next? A. Adsorption using rabbit stroma B. Antigen typing of patient cells C. Elution followed by a cell panel on the eluate D. Selected cell panel

    C. Elution followed by a cell panel on the eluate

  • 2

    A major crossmatch and screening cells are 2+ at IS, 1+ at 37°C, and negative at the IAT phase. Identify the most likely problem. A. Combination of antibodies B. Cold alloantibody C. Rouleaux D. Test error

    B. Cold alloantibody

  • 3

    What corrective action should be taken when rouleaux causes positive test results? A. Perform a saline replacement technique B. Perform an autoabsorption C. Run a panel D. Perform an elution

    A. Perform a saline replacement technique

  • 4

    All of the following are reasons for performing an adsorption, except: A. Separation of mixtures of antibodies B. Removal of interfering substances C. Confirmation of weak antigens on red cells D. Identification of antibodies causing a positive DAT

    D. Identification of antibodies causing a positive DAT

  • 5

    How long must a recipient sample be kept in the blood bank following compatibility testing? A. 3 days B. 5 days C. 7 days D. 10 days

    C. 7 days

  • 6

    What is the crossmatching protocol for platelets and/or plasma? A. Perform a reverse grouping on donor plasma B. No testing is required C. Perform a reverse grouping on recipient plasma D. Platelets must be HLA compatible

    B. No testing is required

  • 7

    What are the compatibility requirements for an autologous unit? A. ABO and Rh typing B. Type and screen C. Major crossmatch D. All of these options

    A. ABO and Rh typing

  • 8

    A patient types as AB positive. Two units of blood have been ordered by the physician. Currently, the inventory shows no AB units, 10 A-positive units, 1 A-negative unit, 5 B-positive units, and 20 O-positive units. Which should be set up for the major crossmatch? A. A-positive units B. O-positive units C. B-positive units D. Call another blood supplier for type-specific blood

    A. A-positive units

  • 9

    Which of the following comprises an abbreviated crossmatch? A. ABO, Rh, and antibody screen B. ABO, Rh, antibody screen, IS crossmatch C. Type and screen D. ABO, Rh, IS crossmatc

    B. ABO, Rh, antibody screen, IS crossmatch

  • 10

    When may an IS crossmatch be performed? A. When a patient is being massively transfused B. When there is no history of antibodies and the current antibody screen is negative C. When blood is being emergency released D. When a patient has not been transfused in the past 3 months

    B. When there is no history of antibodies and the current antibody screen is negative

  • 11

    A patient had a transfusion reaction to packed red blood cells. The medical laboratory scientist began the laboratory investigation of the transfusion reaction by assembling pre- and post-transfusion specimens and all paperwork and computer printouts. What should he do next? A. Perform a DAT on the post-transfusion sample B. Check for a clerical error(s) C. Repeat ABO and Rh typing of patient and donor unit D. Perform an antibody screen on the posttransfusion sample

    B. Check for a clerical error(s)

  • 12

    What is the pathophysiological cause surrounding anaphylactic and anaphylactoid reactions? A. Antibody in patient serum is detected 3–7 days after transfusion, and is attached to donor red blood cells B. Donor plasma has reagins (IgE or IgA) that combine with allergens in patient plasma C. Patient is deficient in IgE and develops IgE antibodies via sensitization from transfusion or pregnancy D. Patient is deficient in IgA and develops IgA antibodies via sensitization from transfusion or pregnancy

    D. Patient is deficient in IgA and develops IgA antibodies via sensitization from transfusion or pregnancy

  • 13

    A patient has a hemolytic reaction to blood transfused 8 days ago. What is the most likely cause? A. Immediate, nonimmunologic probably due to volume overload B. Delayed immunologic, probably due to an antibody such as anti-Jka C. Delayed nonimmunologic, probably due to iron overload D. Immediate, immunologic, probably due to clerical error, ABO incompatibility

    B. Delayed immunologic, probably due to an antibody such as anti-Jka

  • 14

    What may be found in the serum of a person who is exhibiting signs of TRALI (transfusion-related acute lung injury)? A. Red blood cell alloantibody B. IgA antibody C. Antileukocyte antibody D. Allergen

    C. Antileukocyte antibody

  • 15

    Which type of transfusion reaction occurs in about 1% of all transfusions, results in a temperature rise of 1°C or higher, is associated with blood component transfusion, and is not related to the patient’s medical condition? A. Immediate hemolytic B. Delayed hemolytic C. Febrile nonhemolytic reaction D. Transfusion-related acute lung injury

    C. Febrile nonhemolytic reaction

  • 16

    What would be the result of group A blood given to an O patient? A. Nonimmune transfusion reaction B. Immediate hemolytic transfusion reaction C. Delayed hemolytic transfusion reaction D. Febrile nonhemolytic transfusion reaction

    B. Immediate hemolytic transfusion reaction

  • 17

    Patient DB received 2 units of group A-positive red cells 2 days ago. Two days later, he developed a fever and appeared jaundiced. His blood type was A positive. A transfusion reaction workup was ordered. There were no clerical errors detected. A post-transfusion specimen was collected and a DAT performed. The DAT was positive with monospecific anti-IgG. The plasma was also hemolyzed. An antibody screen and panel studies revealed the presence of anti-Jkb (postspecimen). The antibody screen on the pretransfusion specimen was negative. Which of the following explain the positive DAT? A. The donor cells had a positive DAT B. The donor cells were polyagglutinable C. The donor cells were likely positive for the Jkb antigen D. The recipient cells were likely positive for the Jkb antigen

    C. The donor cells were likely positive for the Jkb antigen

  • 18

    All of the following are part of the preliminary evaluation of a transfusion reaction, except: A. Check pre- and post-transfusion samples for color of serum B. Perform ABO and Rh recheck C. DAT on the post-transfusion sample D. Panel on pre- and post-transfusion samples

    D. Panel on pre- and post-transfusion samples

  • 19

    A 68-year-old female diagnosed with neutropenia and inflammation of the left hand was typed as A positive, and received 1 packed red blood cell unit. The antibody screen was negative and crossmatch was compatible. During the transfusion, her pulse was 94, and blood pressure rose from 114/59 to 132/64. Her temperature rose from 37.1°C pretransfusion to 37.8°C 60 minutes after starting transfusion, then to 38.1°C upon completion. A post-transfusion specimen yielded plasma that was neither hemolyzed nor icteric, and a negative DAT. Post-transfusion urinalysis gave a 1+ blood and protein with 10 RBCs/hpf microscopically. The clerical check was acceptable. What type of reaction most likely occurred as a result of transfusion? A. Allergic B. Circulatory overload C. Febrile nonhemolytic D. Delayed hemolytic

    C. Febrile nonhemolytic

  • 20

    A 92-year-old male diagnosed with anemia and episodes of frequent falling was typed as B negative and transfused 1 unit of packed red blood cells, also B negative. He was not recently transfused, and the antibody screen was negative. During the transfusion, his temperature rose from 36.2°C to 36.4°C, his pulse rose from 96 to 124, respirations from 18 to 20, and BP from 127/81 to 174/83. He was transfused with 205 mL before a reaction was called by the transfusionist. The postspecimen DAT was negative and clerical check acceptable. Urinalysis yielded 1+ blood with 5 RBCs microscopically. Other symptoms included tachycardia and flushing. What reaction had most likely taken place? A. Febrile nonhemolytic B. Acute hemolytic C. Anaphylactic D. Volume overload

    D. Volume overload

  • 21

    A 76-year-old female diagnosed with urosepsis was transfused 2 units of packed red blood cells. Her type was AB positive with a negative antibody screen. The units transfused were AB positive. Upon receiving the second unit, the patient became hypoxic with tachypnea. The clerical check was acceptable and DAT negative. She received 269 mL from the second unit before a reaction was called. Her temperature fell from 38°C to 36.4°C, her pulse increased from 72 to 90, and respirations rose from 35 to 41. Her BP was 110/70. The patient expired approximately 12 hours from the time the reaction was called. What type of reaction was most likely present? A. Febrile B. Symptoms not related to transfusion C. Allergic D. TRALI

    B. Symptoms not related to transfusion

  • 22

    A 52-year-old male received 2 units of packed red blood cells as an outpatient in the IV therapy unit. He had a 20-year history of head trauma and was quadriplegic. He had recurrent pneumonia and hematuria due to removal of a Foley catheter. His blood type was A positive with a previously identified anti-Fya. There was an ABO discrepancy in that the A1 cells were positive. The technologist attributed the reaction to the Fya antigen being present on the A1 cells. The patient also had a cold autoantibody. Two units of A-positive packed cells were crossmatched that were Fya negative, and were compatible. One unit was transfused at 11:30 a.m. without incident. The second unit was transfused at 2:16 p.m., and stopped at 3:55 p.m. due to reddish brown–tinged urine discovered in his collection bag. A post-transfusion specimen yielded a positive DAT, and plasma that was grossly hemolyzed. A prewarm crossmatch was incompatible in both the pre- and postspecimen. Anti-E and c were present in the postspecimen. What reaction was most likely present? A. Acute hemolytic B. Febrile C. Allergic D. TRALI

    A. Acute hemolytic

  • 23

    An 82-year-old male was admitted for renal failure. His type was B positive, and his antibody screen was negative. Two units of red cells were ordered. The first unit was transfused at 1:00 p.m. without incident. The second was started at 4:15 p.m. and stopped at 5:12 p.m., after the nurse observed the patient had expired. Vital signs were taken at 4:30 p.m. with no abnormalities. A transfusion reaction was called and the blood unit, tubing, and paperwork sent to the blood bank. There were no clinical manifestations noted on the paperwork and no post-transfusion specimen was sent to the blood bank. What type of reaction most likely occurred? A. Symptoms not related to transfusion B. Acute hemolytic reaction C. Anaphylactic reaction D. Volume overload

    A. Symptoms not related to transfusion